Amgen Inc

Amgen Inc. (NASDAQ: AMGN, SEHK: 4332) is an international biotechnology company headquartered in Thousand Oaks, California. Located in the Conejo Valley, Amgen is the world's largest independent biotech firm. The company employs approximately 17,000 staff members. Its products include Epogen, Aranesp, Enbrel, Kineret, Neulasta, Neupogen, Sensipar / Mimpara, Nplate, and Prolia. Epogen and Neupogen (the company's first products on the market) were the two most successful biopharmaceutical products at the time of their respective releases.

Source: Wikipedia

Campaign Finance

Information

Figures are based on itemized contributions reported to the Federal Election Commission and state agencies. Please note that:

  • contributions under $200 are not reported, and so are not included in totals.
  • only contributions from individuals and organizations to candidates are included. Various accounting measures and more exotic contribution types are excluded.
  • contributions are matched based on organization and recipient name reported within each election cycle. Contributions using an incorrect or non-standard version of the name may be missed.
  • corporate name changes and mergers may cause figures to differ from those of the Center for Responsive Politics.
  • organization totals include known subsidiaries of the organization.

For more information, please see our campaign finance methodology page. Lobbyist bundling data is described on our lobbyist bundling methodology page.

Latest FEC Data

covers through committee's May 31, 2012 filing.
Download all contributions to Amgen Inc

  • Summary

    overview of the committee's finances
    Total Raised:
    $1,348,780
    Total Spent:
    $1,116,399
    Cash on Hand:
    $384,664
    Debts:
    $0

Standardized Donation Information

covers through 2011. may lag behind FEC section above, as donors and industries are identified by hand.

  • Top Recipients

    Employee Color Block
    Individuals
    PAC Color Block
    PAC
    Includes contributions from the organization’s employees, their family members, and its political action committee.

  • Republicans vs. Democrats

    in dollars

  • State vs. Federal

    in dollars

  • Top PAC Recipients

    Employee Color Block
    Individuals
    PAC Color Block
    PAC
    Includes contributions from the organization’s employees, their family members, and its political action committee.
View all campaign finance data for Amgen Inc Sources: OpenSecrets.org FollowTheMoney.org

Lobbying

$7,310,000 Spent
Information

Figures are based on lobbying activity reported to the Senate Office of Public Records. Reported dollar amounts are required to be accurate only to the nearest $20,000. For organizations whose primary business is lobbying, we display total income and top clients. For organizations that are not primarily lobbying firms, we display total amount spent on lobbying and top lobbying firms hired.

For more information, please see our lobbying methodology page.

covers through Q3, 2011

Lobbying On Behalf of Amgen Inc

View all lobbying data for Amgen Inc Sources: Lobbyist Registration Tracker OpenSecrets.org

Regulations

14 Mentions; 4 Submissions
Information

All data is based on documents downloaded from Regulations.gov. The first table shows mentions: all documents that include the name of the company anywhere in the document or document metadata. The second table shows submissions: all documents where the submitter metadata included the company name. Each table shows the top 10 dockets, ranked by number of occurrences.

Matches are based on a search for the company name. Variations in the company name, such as acronyms, nicknames or alternate names may cause documents to be missed. The mention of a company name in a document may be incidental and does not necessarily indicate that the company has any relevance to the document. Company names that are common English words may erroneously match with text that is not referring to the company.

Not all agencies submit public comments to Regulations.gov. For a list of participating and non-participating agencies see here. Agencies that do submit to Regulations.gov have varying levels of accuracy and completeness.

Regulations and public comments can be downloaded in bulk here.

updated from Regulations.gov on September 27, 2011

The tables show occurrences of "Amgen Inc" in public comments on proposed federal regulations.

  • Documents Submitted by the Organization
    • Submissions
    • Agency
    • Docket
    • Date
    • Toggle 1 FDA International Conference on Harmonisation; Draft Guidance on Q11 Development and Manufacture of Drug Substances; Availability 2011
    • Toggle 1 FDA Draft Guidance for Industry on Medication Guide Distribution Requirements and Inclusion of Medication Guides in Risk Evaluation and Mitigation Strategies (REMS); Availability 2011
    • Toggle 1 FDA Biologics Price Competition and Innovation Act of 2009; Options for a User Fee Program for Biosimilar and Interchangeable Biological Product Applications for Fiscal Years 2013 through 2017; Request for Comments 2011
    • Toggle 1 FDA Patent Term Extension Application for PROLIA® (denosumab), U.S. Patent No. 7,411,050 2011
  • Mentions in Document Text
    • Mentions
    • Agency
    • Docket
    • Date
    • Toggle 8 CMS Medicare Program; Changes to the End-Stage Renal Disease Prospective Payment System for CY 2012, End-Stage Renal Disease Quality Incentive Program for PY 2013 and PY 2014; Ambulance Fee Schedule; and Durable Medical Equipment 2011
    • Toggle 2 EPA Nominations to the FIFRA Scientific Advisory Panel; Request for Comments 2011
    • Toggle 2 FDA International Conference on Harmonisation; Draft Guidance on Q11 Development and Manufacture of Drug Substances; Availability 2011
    • Toggle 2 FDA Patent Term Extension Application for PROLIA® (denosumab), U.S. Patent No. 7,411,050 2011
    • Toggle 1 USTR Request for Comments on Possible Negotiations in the World Trade Organization to Expand the Information Technology Agreement, including Its Product Coverage 2011
    • Toggle 1 ITA Request for Public Comments Concerning Regulatory Cooperation Activities that Would Help Eliminate or Reduce Unnecessary Regulatory Divergences in North America that Disrupt U.S. Exports 2011
    • Toggle 1 CMS Medicare: Changes to the End-Stage Renal Disease Prospective Payment System Transition Budget-Neutrality Adjustment 2011
    • Toggle 1 FDA Periodic Review of Existing Regulations; Retrospective Review Under Executive Order 13563 2011
    • Toggle 1 FDA Biologics Price Competition and Innovation Act of 2009; Options for a User Fee Program for Biosimilar and Interchangeable Biological Product Applications for Fiscal Years 2013 through 2017; Request for Comments 2011
    • Toggle 1 FAA Notice of Proposed Modification to the June 1, 2006 MOA FAA/Subscriber Memorandum of Agreement for ASDI/NASSI Industry Access and Request for Comments 2011

Advisory Committees

5 people on 5 committees
Information

Data is based on disclosures required by the Federal Advisory Committee Act (FACA). Matches are based on the occurrence of the company name in the committee member affiliation. Variations in company names may cause some matches to be missed.

The table shows only the top 10 agencies. To search and download raw records from the complete dataset see the FACA data section.

covers through 2011

Table shows employees of "Amgen Inc" that sat on federal advisory committees.

  • Agency
  • Representation
  • Toggle Department of Health and Human Services 2 people on 2 committees
  • Toggle Department of Commerce 1 person on 1 committee
  • Toggle Department of Defense 1 person on 1 committee
  • Toggle National Science Foundation 1 person on 1 committee
View all advisory committee data for Amgen Inc